Phase I PLM-102 Trial for Relapsed, Refractory AML
ClinicalTrials.gov Studies
Summary
A Phase 1 clinical trial (NCT07549464) is investigating PLM-102 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). The study aims to identify the highest tolerable dose of PLM-102 while evaluating its safety profile in this patient population. The trial is registered on ClinicalTrials.gov under NIH oversight.
“The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 1 clinical trial registration (NCT07549464) for PLM-102 has been published on ClinicalTrials.gov under NIH oversight. The study will enroll patients with relapsed and/or refractory AML/MDS to evaluate the highest tolerable dose and safety of PLM-102.
Pharmaceutical companies and clinical investigators involved in oncology drug development should note this early-phase entry in the AML treatment pipeline. Sponsors with competing assets in this indication may wish to monitor enrollment progress and emerging safety signals from this dose-escalation study.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
Phase 1 NCT07549464 Kind: PHASE1 Apr 24, 2026
Abstract
The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.
Conditions: Acute Myeloid Leukemia
Interventions: PLM-102
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.